Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Live is Caixin Global's real-time news portal, featuring 24-hour breaking news, short-form analysis, and roundups from business and social media in China.

TRENDING
CNPC Plans $3.18 Billion Capital Increase in Finance Subsidiary
Retired Shandong Securities Regulator Put Under Probe
China Raises the Bar for Futures Company Shareholders
LATEST
Retired Shandong Securities Regulator Put Under Probe
China Raises the Bar for Futures Company Shareholders
CNPC Plans $3.18 Billion Capital Increase in Finance Subsidiary
Shanghai Regulators Push Didi to Expel Illegal Drivers After Accident
China Posts First Fiscal Revenue Decline in Six Months
A Billion People Are Now Part of China’s Credit Reporting System
Flow of Direct Investment Into China Continues to Grow Despite Trade Tensions
Trade Issues Could Trigger Competitive Devaluation: Ex-Central Bank Chief
Hong Kong Stock Exchange Chief Vows to Root Out Corrupt ‘Vermin’
China’s Property Investment Growth Slows
Shanghai Bets Big on Green Vehicle Future With ‘Hydrogen Energy Port’
Beijing Says Recent Drop in Rare-Earth Exports Caused by Market, Not Tightened Rules
China Proposes Tighter Rules on Foreign Companies Transferring Data Out of Country
Exclusive: Baoshang Takeover Impact Diminishing, Top Regulator Says
Former Top Nanjing Political Adviser Commits Suicide
Warburg-Backed ESR Shelves $1.25 Billion Hong Kong IPO
BMW's Production Shift to China Pays Off With Jump in X3 Sales
China Will Deliver Its Own Entity List Soon, Ministry Says
China Reduces High-Risk Financial Assets by Net $2 Trillion: Regulator
Central Bank Chief Calls on Shanghai to Step Up Services for Global Investors
Deadly 'Super Fungus' Fuels China Pharma Stock Surge

By Wang Luyao and Han Wei / Apr 12, 2019 03:40 AM / Finance

Photo: VCG

Photo: VCG

A number of Chinese pharma stocks surged Thursday after reports confirming domestic infections of a deadly fungus that is spreading around the globe, although none of the companies has a proven therapy.

Share prices of antifungal drugmakers listed in Shanghai and Shenzhen have climbed over the past few days. Several stocks rose by their 10% daily limits, including Jiangsu Lianhuan Pharmaceutical Co. and Jiangsu Sihuan Bioengineering Co.

At least 18 people in China are known to have been infected in recent years with Candida auris, although no deaths have been reported, Caixin learned. The fungus, which can cause deadly infections of the bloodstream and wounds in people with weakened immune systems, is often resistant to common antifungal drugs and is described as a “serious global health threat” by the U.S. Centers for Disease Control and Prevention.

Analysts said the pharma stock surges are mainly driven by hot money as none of the companies has been proven to have effective therapy against Candida auris.


Share this article
Open WeChat and scan the QR code
Copyright © 2019 Caixin Global Limited. All Rights Reserved.